Literature DB >> 29320753

Prognostic significance of S100A16 subcellular localization in lung adenocarcinoma.

Makoto Kobayashi1, Ryo Nagashio1, Keita Saito1, Clemente Aguilar-Bonavides2, Shinichiro Ryuge3, Ken Katono3, Satoshi Igawa3, Benio Tsuchiya1, Shi-Xu Jiang4, Masaaki Ichinoe4, Yoshiki Murakumo4, Makoto Saegusa4, Yukitoshi Satoh5, Yuichi Sato6.   

Abstract

To discover novel tumor markers for lung adenocarcinoma (AC), we performed proteomics analysis and reported a correlation between S100A16 membranous expression in AC tissues and a poor prognosis. However, some patients with a good prognosis also showed S100A16 membranous staining. We re-evaluated immunohistochemically stained tissues, and found membrane-positive and nucleus-negative expressions to be significantly higher in the presence of the following: male, smoker, positive nodal metastasis, higher p-TNM stage, larger tumor, poorer differentiation, positive for lymphatic invasion, positive for vascular invasion, and positive for pleural invasion (all factors P < .05). This pattern of staining was also an independent prognostic factor. Furthermore, we analyzed S100A16 mRNA expression using TCGA and Kaplan-Meier plotter databases, and found that higher S100A16 mRNA expression in AC was significantly correlated with poorer survival. To our knowledge, there has been no comprehensive study focused on both S100A16 protein and mRNA expression levels in AC patients. Our results suggest that the subcellular localization of S100A16 and S100A16 mRNA expression levels is a promising prognostic marker for AC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunohistochemistry; Localization; Lung adenocarcinoma; Prognosis; S100A16

Mesh:

Substances:

Year:  2018        PMID: 29320753     DOI: 10.1016/j.humpath.2018.01.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.

Authors:  Liya Ma; Gen Li; Tianquan Yang; Li Zhang; Xinxin Wang; Xiaowen Xu; Hong Ni
Journal:  Cancer Chemother Pharmacol       Date:  2022-10-12       Impact factor: 3.288

2.  A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.

Authors:  Chenghao Wang; Tong Lu; Ran Xu; Xiaoyan Chang; Shan Luo; Bo Peng; Jun Wang; Lingqi Yao; Kaiyu Wang; Zhiping Shen; Jiaying Zhao; Linyou Zhang
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

3.  Identification of Prognostic Immune-Related Genes by Integrating mRNA Expression and Methylation in Lung Adenocarcinoma.

Authors:  Jie Zhu; Min Wang; Daixing Hu
Journal:  Int J Genomics       Date:  2020-07-09       Impact factor: 2.326

4.  Integrated analysis identifies S100A16 as a potential prognostic marker for pancreatic cancer.

Authors:  Tian Chen; De-Meng Xia; Chao Qian; Shan-Rong Liu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

5.  S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.

Authors:  Shiyu Ou; Yan Liao; Jie Shi; Jing Tang; Yanqing Ye; Fengfei Wu; Weidong Wang; Jieying Fei; Fang Xie; Lan Bai
Journal:  Mol Med Rep       Date:  2020-12-23       Impact factor: 2.952

6.  Analysis of the tumor immune environment identifies an immune gene set-based prognostic signature in non-small cell lung cancer.

Authors:  Guangran Guo; Longjun Yang; Yingsheng Wen; Gongming Wang; Rusi Zhang; Dechang Zhao; Zirui Huang; Xuewen Zhang; Yongbin Lin; Lanjun Zhang
Journal:  Ann Transl Med       Date:  2022-01

7.  A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma.

Authors:  Xiao Zhang; Xiaomian Li; Jun Xie; Qian Zhu; Yufeng Yuan
Journal:  J Oncol       Date:  2022-03-18       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.